Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JaDe treosulfan-based conditioning before allogeneic HSCT in Japanese adults with hematologic malignancies
jRCT2031240305Active, not recruiting
- Sponsor
- medac GmbH
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of treosulfan and fludarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 3 more, sponsored by medac GmbH. Primary endpoints: Dose-limiting toxicities and Time to neutrophil engraftment. Started Jan 2025; status: active, not recruiting.
02
Drugs
treosulfanfludarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on jRCT2031240305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240305.